fig2

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma

Figure 2. Key mechanisms leading to MDR in RMS. Several mechanisms converge in the evolution of cells with acquired MDR. MDR: Multidrug resistance; RMS: rhabdomyosarcomas; RAS: rat sarcoma; PI3K: phosphoinositide 3-kinase; NF-κB: nuclear factor kappa B.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/